Neuroinflammation involving macrophages elevates Prostaglandin E 2 , associated with neuropathic pain. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) inhibits cyclooxygenase, reducing PGE 2 . However, NSAIDs cause physiological complications. We developed nanoemulsions incorporating celecoxib and near infrared dye. Intravenous injected nanoemulsion is incorporated into monocytes that accumulate at the injury; revealed in live animals by fluorescence. A single dose (celecoxib 0.24 mg/kg) provides targeted delivery in chronic constriction injury rats, resulting in significant reduction in the visualized inflammation, infiltration of macrophages, COX-2 and PGE 2 . Animals exhibit relief from hypersensitivity persisting at least four-days. The total body burden of drug is reduced by > 2000 fold over oral drug delivery.
1. Introduction
Chronic pain is difficult to manage
It occurs with a spectrum of neuropathologies often associated with neuroinflammation (Bennett and Xie, 1988; Clatworthy et al., 1995) . It is perpetuated by macrophages expressing cyclooxygenase-2 (COX-2), leading to elevated levels of Prostaglandin E 2 (PGE 2 ), an expression pattern associated with hyper sensitivity and neuropathic pain (Pollard, 2009; Ma and Quirion, 2005; Takahashi et al., 2004; Ma and Quirion, 2006; Durrenberger et al., 2006) . PGE 2 alters neural activity, influences the milieu of cytokines, and changes gene expression in neurons and other cells in ways that contributes to pain (Vasudeva et al., 2014 (Vasudeva et al., , 2015 . Reducing PGE 2 can help to relieve pain and is achieved with non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase. However, reduced efficacy due to poor bioavialibity and lack of specific tissue targeting (Scarpignato et al., 2015; Solomon et al., 2008) means that relatively high doses broadcast throughout the entire body are needed to achieve therapeutic results. This leads to adverse drug reactions on other tissues. To overcome this limitation, we have developed theranostic (diagnostic and therapeutic) nanoemulsions (Patel et al., 2015; Patel and Janjic, 2015; Patel et al., 2013; Liu et al., 2015) . Here we present a newly designed nanoemulsion for the treatment of neuroinflammation that provides targeted delivery of NSAIDs evaluated in chronic constriction injury (CCI) rats. Nanoemulsions with Near Infrared Fluorescence (NIRF) label circulating monocytes, that in turn naturally accumulate at the site of injury as differentiated macrophages. With near IR fluorescence, the site and extent of inflammation is revealed in live animals (Vasudeva et al., 2014) . Here we incorporate the anti-inflammatory drug celecoxib in the nanoemulsion (Patel et al., 2015; Patel and Janjic, 2015; Patel et al., 2013; Liu et al., 2015) demonstrating that a single low dose (0.24 mg/kg) intravenous injection provides targeted delivery of drug. This results in a significant reduction in the NIRF visualized inflammation in live animals, a significant reduction in the number of infiltrating macrophages, as well as a reduction in COX-2 and PGE 2 expression. The animals exhibit a significant relief from hypersensitivity; persisting for at least four-days post-injection. This nanoemulsion therapy represents a reduction of > 2000 fold in the overall body burden of drug needed to provide sustained relief as compared to oral drug delivery (Schafers et al., 2004; Wang et al., 2010) .
Celecoxib, an NSAID, is used in this study as a model COX-2 inhibitor. Celecoxib exhibits very poor water solubility, low bioavailability (Lee et al., 2013) , and is a BCS (biopharmaceutical classification
